SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT ®-HD2 study demonstrating an established long-term safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback